主要文件

查看所有文档

S0360090

(RS)-Selegiline hydrochloride

Name: (<I>RS</I>)-Selegiline hydrochloride
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₃H₁₇N · HCl

化学文摘社编号:

2079-54-1

分子量:

223.74

UNSPSC Code:

41116107

NACRES:

NA.24

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

selegiline

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl.N(C(Cc1ccccc1)C)(CC#C)C

InChI

1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H

InChI key

IYETZZCWLLUHIJ-UHFFFAOYSA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

(RS)-Selegiline hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

法规信息

监管及禁止进口产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.

Chuanjun Lu et al.

European journal of medicinal chemistry, 62, 745-753 (2013-03-05)

A novel series of tacrine-selegiline hybrids was synthesised and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B). The results demonstrate that most of the synthesised compounds exhibit high inhibitory activity. Among these compounds, compound 8g provided

Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.

Qing Zhao et al.

International journal of molecular medicine, 32(4), 883-891 (2013-07-24)

The monoamine oxidase type-B (MAO-B) inhibitor, selegiline, is often recommended as a first-line treatment for Parkinson's disease (PD) and has been shwon to possess neuroprotective effects. The aim of the present study was to determine whether selegiline increases the levels

Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease.

Thomas Müller et al.

Journal of neural transmission (Vienna, Austria : 1996), 120(5), 761-765 (2012-12-01)

The objective of this study is to demonstrate that application of rasagiline instead of selegiline with concomitant determination of L-amphetamine and L-methamphetamine in plasma is safe and well tolerated and influences sleep, mood, and motor behavior in patients with Parkinson's

查看所有相关文献

全球贸易项目编号

货号	GTIN
S0360090	04061836830229